U.S. Food and Drug Administration recently approved the drug Descovy
for use in at-risk teenagers and adults for HIV-1 pre-exposure
prophylaxis in the hopes of decreasing the chance of becoming
infected with HIV-1 infection through sexual contact.
drawback? The FDA has not approved the drug for people who have
vaginal sex, as studies have not been conducted to determine the
to the FDA’s Center for Drug Evaluation and Research Deputy
Director of Division of Antiviral Products Dr. Jeffrey Murray, the
approval offers more prevention choices for some patients who may be
at risk for catching HIV. It
also helps increase the U.S. Department of Health and Human Services
and FDA to further the development of both HIV prevention and
treatment in the hopes of reducing HIV infections.
2017, the CDC said nearly 39,000 people were told they had HIV, and
to combat the issue, President Donald Trump announced the “Ending
the HIV Epidemic: A Plan for America” initiative during the State
of the Union address Feb. 5, 2019.
chance to alleviate any chance for new U.S. HIV infections means
giving the hardest-hit communities the latest resources, technologies
and expertise that will address it. The goal is to decrease the rate
of new infections by 75 percent within five years and 90 percent
within the next 10 years. By doing so, it would mean 250,000 new HIV
infections would not take place.
(pre-exposure prophylaxis) is the one HIV prevention method people
without HIV can take every day to decrease their chances of catching
the virus that causes AIDS if exposed to it. Descovy use for PrEP
needs to be added to an already broad strategy, such as practicing
safe sex and adhering to the daily use.
for PrEP was reviewed for safety and efficiency in a random
multinational trial of nearly 5,400 HIV negative men and transgender
women having sex with men and at a heightened risk of getting HIV-1.
The trial looked at once-daily Descovy to Truvada, which also helps
to reduce the rate of HIV-1 infection. The drug trial participants
were followed up to 96 weeks.
the end of the trial, Descovy’s rate of infection prevention was
nearly identical to Truvada, but the most common side effect for
Descovy was diarrhea.
with hepatitis B and use Descovy should be mindful that not using
tenofovir disproxil fumarate or emtricitabine to treat HBV problems
could cause them to worsen. Descovy should only be given to those
individuals who have tested negative for HIV the last three months.
The FDA approved Descovy’s use in 2016 for use with other antiretroviral drugs in the treatment of HIV-1 infection in both pediatric and adult patients.